![](/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBHQT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--e623d2450603cd9d4e6c86eae39da2c5b7f7bdd9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdERG9MY21WemFYcGxTU0lOTXpJd2VERTRNRjRHT2daRlZEb0pZM0p2Y0VraUVETXlNSGd4T0RBck1Dc3dCanNHVkRvTVozSmhkbWwwZVVraUMyTmxiblJsY2dZN0JsUTZESEYxWVd4cGRIbHBWVG9LYzNSeWFYQlVPZzVwYm5SbGNteGhZMlZKSWdsTWFXNWxCanNHVkRvTFpHVm1hVzVsU1NJZWFuQmxaenBtWVc1amVTMTFjSE5oYlhCc2FXNW5QVzltWmdZN0JsUT0iLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--daee5f4cd191d67586af9b48495fbde7d4763d64/lucas-vasques-453684-unsplash.jpg)
Search
Selected Filter
Filter Results
Displaying 11–20 of 409 diseases results
-
Jun 13, 2024
Beacon Doses First Patient in its Phase 2/3 VISTA Clinical Trial for XLRP Gene Therapy
The company plans to apply for regulatory approval for the gene therapy with data from VISTA and its earlier clinical trials.
-
Jun 7, 2024
Eye on the Cure Podcast | Episode 67: Dr. Peter Campochiaro
Dr. Peter Campochiaro, a clinician-scientist and the Eccles Professor of Ophthalmology and Neuroscience at the Johns Hopkins University School of Medicine, talks to host Ben Shaberman about N-acetylcysteine (NAC), a drug that shows promise for preserving cone vision (central vision and acuity) in people with retinitis pigmentosa. The powerful antioxidant has moved into a 30+ site, Phase 3 clinical trial called NAC Attack.
-
Jun 5, 2024
Antabuse Moves into Clinical Trial for People with RP
Researchers believe the FDA-approved drug can reduce the hyperactivity of ganglion cells to improve vision.
-
May 22, 2024
ARVO 2024 Highlight: InGel’s Cell Therapy Shows Promise for Preserving Vision
The emerging treatment is designed to work for people with RP and other conditions regardless of the gene mutation causing disease
-
May 22, 2024
Advancing Research Solutions for PRPH2-Associated Retinal Diseases.
-
May 16, 2024
No serious adverse events were reported. One patient had encouraging improvement in retinal sensitivity.
-
May 14, 2024
ARVO 2024 Highlight: New Gene Linked to RP in People with African Ancestry
The discovery will help geneticists diagnose more RP patients with African descent.
-
May 10, 2024
ARVO 2024 Highlight: Positive Two-Year Results from PDE6B Gene Therapy Clinical Trial
Mutations in PDE6B are a leading cause of retinitis pigmentosa.
-
May 6, 2024
In honor of the upcoming Mother’s Day, New York Times, USA Today, and Wall Street Journal bestselling author Jennifer Probst is sharing her personal story of her son’s diagnosis with Stargardt disease.
-
May 2, 2024
Atsena’s XLRS Gene Therapy Shows Efficacy in Phase 1/2 Clinical Trial
The XLRS gene therapy was well tolerated and resolved damaging schisis cavities in patients receiving the lowest dose.